Search Results

Return to List
Results 1–20 of 22
Title Date
1.

Avoiding Inappropriate Clinical Decisions Based on False-Positive Human Chorionic Gonadotropin Test Results

Number 278

(Reaffirmed 2013)

ABSTRACT: Clinically significant false-positive human chorionic gonadotropin (hCG) test results are rare. However, some individuals have circulating factors in their serum (eg, heterophilic antibodies or nonactive forms of hCG) that interact with the hCG antibody and cause unusual or unexpected te...

November 2002

PDF Format
2.

Guidelines for Diagnostic Imaging During Pregnancy

Number 299

(Reaffirmed 2009, Replaces No. 158, September 1995)

ABSTRACT: Undergoing a single diagnostic X-ray procedure does not result in radiation exposure adequate to threaten the well-being of the developing preembryo, embryo, or fetus and is not an indication for therapeutic abortion. When multiple diagnostic X-rays are anticipated during pregnancy, imag...

September 2004

PDF Format
3.

Screening for Tay - Sachs Disease

Number 318

(Reaffirmed 2014, Replaces No. 162, November 1995)

ABSTRACT: Tay–Sachs disease (TSD) is a severe progressive neurologic disease that causes death in early childhood. Carrier screening should be offered before pregnancy to individuals and couples at high risk, including those of Ashkenazi Jewish, French–Canadian, or Cajun descent and those with a f...

October 2005

PDF Format
4.

Inappropriate Use of the Terms Fetal Distress and Birth Asphyxia

Number 326

ABSTRACT: The Committee on Obstetric Practice is concerned about the continued use of the term "fetal distress" as an antepartum or intrapartum diagnosis and the term "birth asphyxia" as a neonatal diagnosis. The Committee reaffirms that the term fetal distress is imprecise and nonspecific. The co...

December 2005

PDF Format
5.

The Apgar Score

Number 333

(Reaffirmed 2010, Replaces No. 174, July 1996)

ABSTRACT: The Apgar score provides a convenient shorthand for reporting the status of the newborn infant and the response to resuscitation. The Apgar score has been used inappropriately to predict specific neurologic outcome in the term infant. There are no consistent data on the significance of t...

May 2006

PDF Format
6.

Umbilical Cord Blood Gas and Acid-Base Analysis

Number 348

(Reaffirmed 2012)

ABSTRACT: Umbilical cord blood gas and acid-base assessment are the most objective determinations of the fetal metabolic condition at the moment of birth. Moderate and severe newborn encephalopathy, respiratory complications, and composite complication scores increase with an umbilical arterial ba...

November 2006

PDF Format
7.

Fetal Monitoring Prior to Scheduled Cesarean Delivery

Number 382

(Reaffirmed 2010)

ABSTRACT: There are insufficient data to determine the value of fetal monitoring prior to scheduled cesarean delivery in patients without risk factors. With the increasing rate of scheduled cesarean deliveries in the United States, clinicians and hospitals must decide whether there is need to ...

October 2007

PDF Format
8.

Human Immunodeficiency Virus

Number 389

ABSTRACT: Because human immunodeficiency virus (HIV) infection often is detected through prenatal and sexually transmitted disease testing, an obstetrician–gynecologist may be the first health professional to provide care for a woman infected with HIV. Universal testing with patient notification a...

December 2007

PDF Format
9.

Preconception and Prenatal Carrier Screening for Genetic Diseases in Individuals of Eastern European Jewish Descent

Number 442

(Reaffirmed 2014, Replaces No. 298, August 2004)

ABSTRACT: Certain autosomal recessive disease conditions are more prevalent in individuals of Eastern European Jewish (Ashkenazi) descent. Previously, the American College of Obstetricians and Gynecologists recommended that individuals of Eastern European Jewish ancestry be offered carrier screeni...

October 2009

PDF Format
10.

Screening for Depression During and After Pregnancy

Number 453

(Reaffirmed 2012)

Abstract: Depression is very common during pregnancy and the postpartum period. At this time, there is insufficient evidence to support a firm recommendation for universal antepartum or postpartum screening. There are also insufficient data to recommend how often screening should be done. There ar...

February 2010

PDF Format
11.

Carrier Screening for Fragile X Syndrome

Number 469

(Replaces No. 338, June 2006)

ABSTRACT: Fragile X syndrome is the most common inherited form of mental retardation. The syndrome occurs in approximately 1 in 3,600 males and 1 in 4,000–6,000 females. Approximately 1 in 250 females carry the premutation. DNA-based molecular analysis is the preferred method of diagnosis for frag...

October 2010

PDF Format
12.

Newborn Screening

Number 481

(Replaces No. 393, December 2007)

ABSTRACT: Newborn screening programs are mandatory, state-based public health programs. They provide newborns in the United States with presymptomatic testing and necessary follow-up care for a variety of medical conditions for which early intervention will improve neonatal and long-term health ou...

March 2011

PDF Format
13.

Update on Carrier Screening for Cystic Fibrosis

Number 486

(Replaces No. 325, December 2005)

ABSTRACT: In 2001, the American College of Obstetricians and Gynecologists and the American College of Medical Genetics introduced guidelines for prenatal and preconception carrier screening for cystic fibrosis. The American College of Obstetricians and Gynecologists' Committee on Genetics has upd...

April 2011

PDF Format
14.

At-Risk Drinking and Alcohol Dependence: Obstetric and Gynecologic Implications

Number 496

(Reaffirmed 2013)

ABSTRACT: Compared with men, at-risk alcohol use by women has a disproportionate effect on their health and lives, including reproductive function and pregnancy outcomes. Obstetrician–gynecologists have a key role in screening and providing brief intervention, patient education, and treatment refe...

August 2011

PDF Format
15.

Intimate Partner Violence

Number 518

ABSTRACT: Intimate partner violence (IPV) is a significant yet preventable public health problem that affects millions of women regardless of age, economic status, race, religion, ethnicity, sexual orientation, or educational background. Individuals who are subjected to IPV may have lifelong conse...

February 2012

PDF Format
16.

Placenta Accreta

Number 529

(Reaffirmed 2014)

ABSTRACT: Placenta accreta is a potentially life-threatening obstetric condition that requires a multidisciplinary approach to management. The incidence of placenta accreta has increased and seems to parallel the increasing cesarean delivery rate. Women at greatest risk of placenta accreta are tho...

July 2012

PDF Format
17.

Lead Screening During Pregnancy and Lactation

Number 533

ABSTRACT: Prenatal lead exposure has known adverse effects on maternal health and infant outcomes across a wide range of maternal blood lead levels. Adverse effects of lead exposure are being identified at lower levels of exposure than previously recognized in both children and adults. In 2010, th...

August 2012

PDF Format
18.

Reproductive Health Care for Incarcerated Women and Adolescent Females

Number 535

ABSTRACT: Increasing numbers of women and adolescent females are incarcerated each year in the United States and they represent an increasing proportion of inmates in the U.S. correctional system. Incarcerated women and adolescent females often come from disadvantaged environments and have high ra...

August 2012

PDF Format
19.

Noninvasive Prenatal Testing for Fetal Aneuploidy

Number 545

ABSTRACT: Noninvasive prenatal testing that uses cell free fetal DNA from the plasma of pregnant women offers tremendous potential as a screening tool for fetal aneuploidy. Cell free fetal DNA testing should be an informed patient choice after pretest counseling and should not be part of routine p...

December 2012

PDF Format
20.

Solutions for Surgical Preparation of the Vagina

Number 571

ABSTRACT: Currently, only povidone-iodine preparations are approved for vaginal surgical-site antisepsis. However, there are compelling reasons to consider chlorhexidine gluconate solutions for off-label use in surgical preparation of the vagina, especially in women with allergies to iodine. Altho...

September 2013

PDF Format